Clinical research
In the trial, 396 patients with moderate-to-severe psychotic symptoms related to adult schizophrenia received either Nuplazid or placebo added to their current antipsychotic treatment. The patients receiving Nuplazid showed a consistent trend in symptom improvement but did not hit statistical significance on the primary endpoint.
At 96 weeks, 60% of the heavily pretreated HIV patients dosed with ViiV’s experimental treatment achieved virologic suppression.
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.
Arcutis, Inc., a privately held immuno-dermatology drug development company addressing significant unmet needs in dermatology, announced positive top line results for its Phase 2b study evaluating ARQ-151 as a potential topical treatment for plaque psoriasis.
While the trial did not hit its goals, Intec said data review has shown that certain subsets of patients saw a meaningful reduction in OFF time.
Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
InflaRx reported additional in-depth analysis of the completed double blind, placebo controlled part of the ongoing international SHINE Phase IIb study to supplement InflaRx’s top line disclosure of results reported on June 5, 2019.
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
PRESS RELEASES